Empagliflozin induces a myocardial metabolic shift from glucose consumption to ketone metabolism that mitigates adverse cardiac remodeling and improves myocardial contractility - Santos-Gallego, C G; Ibanez, JA R; San Antonio, R (J Am Coll Cardiol, 2018)
et al.